Development and deployment of COVID-19 vaccines forthose most vulnerable

Wayne C. Koff; Theodore Schenkelberg; Tere Williams; Ralph S. Baric; McDermott Adrian McDermott; Cheryl M. Cameron; Mark J. Cameron; Matthew B. Friemann; Gabriele Neumann; Yoshihiro Kawaoka; Alyson A. Kelvin; Ted M. Ross; Stacey Schultz-Cherry; Timothy D. Mastro; Frances H. Priddy; Kristine A. Moore; Julia T. Ostrowsky; Michael T. Osterholm; Jaap Goudsmit

doi:10.1126/scitranslmed.abd1525

Development and deployment of COVID-19 vaccines forthose most vulnerable

Wayne C. Koff, Theodore Schenkelberg, Tere Williams, Ralph S. Baric, McDermott Adrian McDermott, Cheryl M. Cameron, Mark J. Cameron, Matthew B. Friemann, Gabriele Neumann, Yoshihiro Kawaoka, Alyson A. Kelvin, Ted M. Ross, Stacey Schultz-Cherry, Timothy D. Mastro, Frances H. Priddy, Kristine A. Moore, Julia T. Ostrowsky, Michael T. Osterholm, Jaap Goudsmit

Center for Infectious Disease Research and Policy

Research output: Contribution to journal › Review article › peer-review

50 Scopus citations

Abstract

Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

Original language	English (US)
Article number	eabd1525
Journal	Science Translational Medicine
Volume	13
Issue number	579
DOIs	https://doi.org/10.1126/scitranslmed.abd1525
State	Published - Feb 3 2021

Bibliographical note

Funding Information:
W.C.K., T.S., and J.G. are supported by the Human Vaccines Project donor network. A.M. is supported by NIAID. C.M.C., M.J.C., and A.A.K. are funded by the Canadian Institutes for Health Research Rapid Response Grant for COVID-19. Y.K. is supported by a Research Program on Emerging and Re-emerging Infectious Diseases from AMED (19fk0108113). Y.K. and G.N. are supported by NIAID (grant no. HHSN272201400008C). T.M.R. is supported by an Emory-UGA-CEIRS grant (no. HHSN272201400004C). S.S.-C. is supported in part by ALSAC and by NIAID (grant no. HHSN272201400006C). T.M.R. and S.S.-C. are also supported by NIAID (grant no. 75N93019C00052). M.T.O., K.A.M., and J.T.O. are supported by the Wellcome Trust and by NIAID (grant no. HHSN272201400006C). Y.K. has received funding from Bharat Biotech.

Publisher Copyright:
Copyright © 2021 The Authors.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1126/scitranslmed.abd1525

Find It

Find It at U of M Libraries

Cite this

Koff, W. C., Schenkelberg, T., Williams, T., Baric, R. S., Adrian McDermott, M., Cameron, C. M., Cameron, M. J., Friemann, M. B., Neumann, G., Kawaoka, Y., Kelvin, A. A., Ross, T. M., Schultz-Cherry, S., Mastro, T. D., Priddy, F. H., Moore, K. A., Ostrowsky, J. T., Osterholm, M. T., & Goudsmit, J. (2021). Development and deployment of COVID-19 vaccines forthose most vulnerable. Science Translational Medicine, 13(579), Article eabd1525. https://doi.org/10.1126/scitranslmed.abd1525

Koff, WC, Schenkelberg, T, Williams, T, Baric, RS, Adrian McDermott, M, Cameron, CM, Cameron, MJ, Friemann, MB, Neumann, G, Kawaoka, Y, Kelvin, AA, Ross, TM, Schultz-Cherry, S, Mastro, TD, Priddy, FH, Moore, KA , Ostrowsky, JT , Osterholm, MT & Goudsmit, J 2021, 'Development and deployment of COVID-19 vaccines forthose most vulnerable', Science Translational Medicine, vol. 13, no. 579, eabd1525. https://doi.org/10.1126/scitranslmed.abd1525

@article{2725574722d146d28582f0c6e7540597,

title = "Development and deployment of COVID-19 vaccines forthose most vulnerable",

abstract = "Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.",

author = "Koff, {Wayne C.} and Theodore Schenkelberg and Tere Williams and Baric, {Ralph S.} and {Adrian McDermott}, McDermott and Cameron, {Cheryl M.} and Cameron, {Mark J.} and Friemann, {Matthew B.} and Gabriele Neumann and Yoshihiro Kawaoka and Kelvin, {Alyson A.} and Ross, {Ted M.} and Stacey Schultz-Cherry and Mastro, {Timothy D.} and Priddy, {Frances H.} and Moore, {Kristine A.} and Ostrowsky, {Julia T.} and Osterholm, {Michael T.} and Jaap Goudsmit",

note = "Funding Information: W.C.K., T.S., and J.G. are supported by the Human Vaccines Project donor network. A.M. is supported by NIAID. C.M.C., M.J.C., and A.A.K. are funded by the Canadian Institutes for Health Research Rapid Response Grant for COVID-19. Y.K. is supported by a Research Program on Emerging and Re-emerging Infectious Diseases from AMED (19fk0108113). Y.K. and G.N. are supported by NIAID (grant no. HHSN272201400008C). T.M.R. is supported by an Emory-UGA-CEIRS grant (no. HHSN272201400004C). S.S.-C. is supported in part by ALSAC and by NIAID (grant no. HHSN272201400006C). T.M.R. and S.S.-C. are also supported by NIAID (grant no. 75N93019C00052). M.T.O., K.A.M., and J.T.O. are supported by the Wellcome Trust and by NIAID (grant no. HHSN272201400006C). Y.K. has received funding from Bharat Biotech. Publisher Copyright: Copyright {\textcopyright} 2021 The Authors.",

year = "2021",

month = feb,

day = "3",

doi = "10.1126/scitranslmed.abd1525",

language = "English (US)",

volume = "13",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "579",

}

TY - JOUR

T1 - Development and deployment of COVID-19 vaccines forthose most vulnerable

AU - Koff, Wayne C.

AU - Schenkelberg, Theodore

AU - Williams, Tere

AU - Baric, Ralph S.

AU - Adrian McDermott, McDermott

AU - Cameron, Cheryl M.

AU - Cameron, Mark J.

AU - Friemann, Matthew B.

AU - Neumann, Gabriele

AU - Kawaoka, Yoshihiro

AU - Kelvin, Alyson A.

AU - Ross, Ted M.

AU - Schultz-Cherry, Stacey

AU - Mastro, Timothy D.

AU - Priddy, Frances H.

AU - Moore, Kristine A.

AU - Ostrowsky, Julia T.

AU - Osterholm, Michael T.

AU - Goudsmit, Jaap

N1 - Funding Information: W.C.K., T.S., and J.G. are supported by the Human Vaccines Project donor network. A.M. is supported by NIAID. C.M.C., M.J.C., and A.A.K. are funded by the Canadian Institutes for Health Research Rapid Response Grant for COVID-19. Y.K. is supported by a Research Program on Emerging and Re-emerging Infectious Diseases from AMED (19fk0108113). Y.K. and G.N. are supported by NIAID (grant no. HHSN272201400008C). T.M.R. is supported by an Emory-UGA-CEIRS grant (no. HHSN272201400004C). S.S.-C. is supported in part by ALSAC and by NIAID (grant no. HHSN272201400006C). T.M.R. and S.S.-C. are also supported by NIAID (grant no. 75N93019C00052). M.T.O., K.A.M., and J.T.O. are supported by the Wellcome Trust and by NIAID (grant no. HHSN272201400006C). Y.K. has received funding from Bharat Biotech. Publisher Copyright: Copyright © 2021 The Authors.

PY - 2021/2/3

Y1 - 2021/2/3

N2 - Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

AB - Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.

UR - http://www.scopus.com/inward/record.url?scp=85101252814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101252814&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.abd1525

DO - 10.1126/scitranslmed.abd1525

M3 - Review article

C2 - 33536277

AN - SCOPUS:85101252814

SN - 1946-6234

VL - 13

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 579

M1 - eabd1525

ER -

Development and deployment of COVID-19 vaccines forthose most vulnerable

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this